Entrada Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TRDA Nasdaq 2830 www.entradatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates - Aug 5th, 2026 7:00 am
Entrada Therapeutics Reports Second Quarter 2026 Financial Results - Aug 5th, 2026 5:00 am
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates - Aug 3rd, 2026 6:05 am
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates - Jul 30th, 2026 7:35 am
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study - Jun 2nd, 2026 5:00 am
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 1st, 2026 2:30 pm
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile - May 9th, 2026 12:07 am
Entrada’s stock drops as DMD drug’s efficacy falls short - May 8th, 2026 4:39 am
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy? - May 7th, 2026 2:04 pm
Sector Update: Health Care Stocks Softer Late Afternoon - May 7th, 2026 1:44 pm
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates - May 7th, 2026 6:50 am
Entrada shares dive as Duchenne results disappoint - May 7th, 2026 5:14 am
Entrada Therapeutics Reports First Quarter 2026 Financial Results - May 7th, 2026 5:10 am
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study - May 7th, 2026 5:00 am
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 - May 6th, 2026 2:30 pm
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - May 5th, 2026 7:12 am
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit - Mar 18th, 2026 12:08 pm
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit - Mar 18th, 2026 11:54 am
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Feb 26th, 2026 5:00 am